04 Feb 2014, BioSpectrum Bureau , BioSpectrum
Bangalore: Suven Life Sciences received three product patents one each from Canada (2600271), China (CN 101544592B) and India (257850) for its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The patents are valid through 2025.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
Suven now has a total of 14, 12 and 17 patents from Canada, China and India respectively. These granted patents are exclusive intellectual property (IP) of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase I or phase II.
Suven, whose products are first in class or best in class CNS therapies through the use of GPCR targets, has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Mr Venkat Jasti, CEO, Suven.